Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-420-4 | CAS number: 69430-40-6 DC 5067
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- December 18, 1990 - June 24, 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Report date:
- 1991
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
Test material
- Reference substance name:
- α-trimethylsilanyl-ω-trimethylsiloxypoly[oxy(methyl-3-(2-(2-methoxypropoxy)propoxy)propylsilanediyl]-co-oxy(dimethylsilane))
- EC Number:
- 406-420-4
- EC Name:
- α-trimethylsilanyl-ω-trimethylsiloxypoly[oxy(methyl-3-(2-(2-methoxypropoxy)propoxy)propylsilanediyl]-co-oxy(dimethylsilane))
- Cas Number:
- 69430-40-6
- Molecular formula:
- Unspecified example: C18.3H46.8O5.8Si4.1
- IUPAC Name:
- 2,2,4,4,6,12,15-heptamethyl-6-[(trimethylsilyl)oxy]-3,5,10,13,16-pentaoxa-2,4,6-trisilaheptadecane
- Details on test material:
- - Name of test material (as cited in study report): DC 5067
- Substance type: Reaction mass (mixture)
- Physical state: Liquid
- Analytical purity: > 99%
- Lot/batch No.: AB 090122
- Expiration date of the lot/batch: December 1, 1991
- Stability under test conditions: Stable
- Storage condition of test material: In the original container at room temperature in the dark
- Other:
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Himalayan
- Sex:
- female
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal and epicutaneous
- Vehicle:
- propylene glycol
- Concentration / amount:
- Intradermal induction: 2.5% w/w in propylene glycol
Epidermal induction: 50% w/w in propylene glycol
Challenge:
a = 10% (w/w) in propylene glycol
b = 3% (w/w) in propylene glycol
c = 1% (w/w) in propylene glycol
d = propylene glycol
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- propylene glycol
- Concentration / amount:
- Intradermal induction: 2.5% w/w in propylene glycol
Epidermal induction: 50% w/w in propylene glycol
Challenge:
a = 10% (w/w) in propylene glycol
b = 3% (w/w) in propylene glycol
c = 1% (w/w) in propylene glycol
d = propylene glycol
- No. of animals per dose:
- Experimental group: 20 (females)
Control group: 10 (females)
Results and discussion
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 3%
- No. with + reactions:
- 3
- Total no. in group:
- 20
- Clinical observations:
- redness, swelling and/or scaliness
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 3%. No with. + reactions: 3.0. Total no. in groups: 20.0. Clinical observations: redness, swelling and/or scaliness.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 3%
- No. with + reactions:
- 4
- Total no. in group:
- 20
- Clinical observations:
- redness, swelling and/or scaliness
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 3%. No with. + reactions: 4.0. Total no. in groups: 20.0. Clinical observations: redness, swelling and/or scaliness.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 1%
- No. with + reactions:
- 2
- Total no. in group:
- 20
- Clinical observations:
- redness, swelling and/or scaliness
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 1%. No with. + reactions: 2.0. Total no. in groups: 20.0. Clinical observations: redness, swelling and/or scaliness.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 1%
- No. with + reactions:
- 4
- Total no. in group:
- 20
- Clinical observations:
- redness, swelling and/or scaliness
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 1%. No with. + reactions: 4.0. Total no. in groups: 20.0. Clinical observations: redness, swelling and/or scaliness.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 3%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no skin reaction
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 3%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no skin reaction.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 3%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no skin reaction
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 3%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no skin reaction.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 1%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no skin reaction
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 1%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no skin reaction.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 1%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no skin reaction
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 1%. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: no skin reaction.
Any other information on results incl. tables
PRIMARY IRRITATION EXPERIMENTS
No signs of systemic toxicity were observed during the primary irritation experiments. However body weight loss was noted in one of the five animals. The choice of propylene glycol as vehicle in this test was based on the following: - the test substance dissolved well in propylene glycol at the concentrations used. - the test substance is stable in propylene glycol.
In accordance with Magnusson and Kligman (1969), based on the findings in the primary irritation experiments and from the test substance concentrations tested in the first inconclusive Maximization Test, the following concentrations were selected for the induction and challenge phase:
Intradermal induction: 50% (w/w) in propylene glycol
Challenge: a = 10% (w/w) in propylene glycol
b = 3% (w/w) in propylene propylene
c = 1% (w/w) in propylene glycol
d = propylene glycol
MAIN STUDY
INDUCTION All experimental animals showed slight or moderate erythema and slight oedema after the 48 hours occluded epidermal induction exposure.
FIRST CHALLENGE
CONTROL GROUP:
All ten animals showed a skin reaction in response to the 10% test substance concentration. These skin reactions were characterised by redness, swelling and/or scaliness. No skin reactions were observed in response to the 3% and 1% concentrations.
EXPERIMENTAL GROUP:
Fourteen, four and four animals showed a skin reaction in response to the l0%, 3% and 1% test substance concentrations. These reactions were characterised by redness, swelling and/or scaliness (see table 3, Appendix 1). Taking into account the intensity of the responses and comparing these with the reactions seen in the control animals, four of the animals showed a positive skin reaction in response to the 3% and 1% concentrations. No animals showed a positive skin reaction in response to the 10% concentration.
TOXICITY SYMPTOMS / MORTALITY
No symptoms of systemic toxicity were observed in the animals during the study. No mortality occurred during the study.
BODY WEIGHTS
A marked difference in the average body weight gain of experimental and control animals was noted.
Applicant's summary and conclusion
- Interpretation of results:
- sensitising
- Remarks:
- Migrated information mild sensitizing properties
- Conclusions:
- These results lead to a sensitisation rate of 20 per cent, which indicates that DC-5067 has mild sensitizing properties in this test applying the rating of allergenicity described by Kligman A.M. (1966).
- Executive summary:
The study was entitled "Assessment for Contact Hypersensitivity to DC-5067 in the Albino Guinea Pig (Maximization Test)". The purpose of the study was to obtain information on the potential of DC-5067 to induce delayed contact hypersensitivity (skin sensitization) in the guinea pig after intradermal and epidermal exposures. This study was carried out in accordance with the OECD Guideline Number 406 and in accordance with the method described by Magnusson and Klingman. The experimental animals were intradermally injected with a 2.5% concentration and epidermally exposed with a 50% concentration. Two weeks after the epidermal application all animals were challenged with the following test substance concentrations (10%, 3% and 1%) and the vehicle (propylene glycol). The epidermal exposure of DC-5067 in the introduction phase resulted in slight to moderate skin irritation. The epidermal exposure of DC-5067 in the challenge phase resulted in four positive sensitization reactions in response to the 3% and 1% test substance concentrations. Under the conditions used in this study, DC-5067 resulted in a sensitization rate of 20%. Applying the rating of allergenicity described by Klingman, A. M. (-1966) on the results obtained in this test, DC-5067 is considered to have mild sensitizing properties. Applying the EEC criteria-for classification, DC-5067 need not be labeled as a skin sensitizer.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
